India Gelatine Q2 FY27: revenue Rs 4,520.49 lakh, PAT up 12.4% YoY
India Gelatine & Chemicals’ standalone Q2 FY27 revenue was Rs 4,520.49 lakh and PAT rose to Rs 723.96 lakh from Rs 644.22 lakh a year earlier.
Key takeaways
- Revenue from operations Rs 4,520.49 lakh vs Rs 4,690.24 lakh in Q2 FY26
- Total income Rs 4,648.19 lakh vs Rs 4,874.30 lakh in the year-ago quarter
- Total expenses Rs 3,683.44 lakh vs Rs 3,954.19 lakh in Q2 FY26
- PBT Rs 964.75 lakh vs Rs 920.11 lakh in the corresponding quarter
- PAT Rs 723.96 lakh vs Rs 644.22 lakh; EPS Rs 10.21 vs Rs 9.08
Q2 FY27 · standalone
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 4,520.49 lakh | Rs 4,690.24 lakh | -3.6% |
| PAT | Rs 723.96 lakh | Rs 644.22 lakh | +12.4% |
| EPS | Rs 10.21 | Rs 9.08 | +12.4% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 16.02% of revenue, up 227 bps from 13.74%.
- Revenue fell 3.6% while total expenses fell 6.8%.
• Revenue from operations (Q2 FY27): Rs 4,520.49 lakh vs Rs 4,690.24 lakh in Q2 FY26
• Total income (Q2 FY27): Rs 4,648.19 lakh vs Rs 4,874.30 lakh in Q2 FY26
• Total expenses (Q2 FY27): Rs 3,683.44 lakh vs Rs 3,954.19 lakh in Q2 FY26
• Cost of materials consumed (Q2 FY27): Rs 1,768.37 lakh vs Rs 1,656.83 lakh in Q2 FY26
• Changes in inventories of finished goods, work-in-progress and stock-in-trade (Q2 FY27): Rs (47.72) lakh vs Rs 453.64 lakh in Q2 FY26
• Employee benefits expense (Q2 FY27): Rs 183.94 lakh vs Rs 156.55 lakh in Q2 FY26
• Finance costs (Q2 FY27): Rs 11.27 lakh vs Rs 10.78 lakh in Q2 FY26
• Depreciation and amortisation expense (Q2 FY27): Rs 115.04 lakh vs Rs 116.37 lakh in Q2 FY26
• Other expenses (Q2 FY27): Rs 989.09 lakh vs Rs 899.84 lakh in Q2 FY26
• Profit before tax – PBT (Q2 FY27): Rs 964.75 lakh vs Rs 920.11 lakh in Q2 FY26
• Profit for the period – PAT (Q2 FY27): Rs 723.96 lakh vs Rs 644.22 lakh in Q2 FY26
• Basic EPS (Rs 10 each, not annualised, Q2 FY27): Rs 10.21 vs Rs 9.08 in Q2 FY26
• Diluted EPS (Rs 10 each, not annualised, Q2 FY27): Rs 10.21 vs Rs 9.08 in Q2 FY26
According to the standalone statement of unaudited financial results for the quarter ended 30-09-2026, India Gelatine & Chemicals reported revenue from operations of Rs 4,520.49 lakh, lower than Rs 4,690.24 lakh in the corresponding quarter ended 30-09-2025. Total income for the quarter was Rs 4,648.19 lakh compared with Rs 4,874.30 lakh a year earlier. Total expenses decreased to Rs 3,683.44 lakh from Rs 3,954.19 lakh in the same quarter last year.
Within expenses, cost of materials consumed rose to Rs 1,768.37 lakh from Rs 1,656.83 lakh, while changes in inventories of finished goods, work-in-progress and stock-in-trade moved to Rs (47.72) lakh from Rs 453.64 lakh. Employee benefits expense increased to Rs 183.94 lakh from Rs 156.55 lakh, and finance costs were Rs 11.27 lakh versus Rs 10.78 lakh. Depreciation and amortisation expense was Rs 115.04 lakh compared with Rs 116.37 lakh. Other expenses rose to Rs 989.09 lakh from Rs 899.84 lakh.
Profit before tax for the quarter ended 30-09-2026 stood at Rs 964.75 lakh, up from Rs 920.11 lakh in the quarter ended 30-09-2025. After total tax expenses of Rs 240.79 lakh (vs Rs 275.89 lakh a year earlier), profit for the period was Rs 723.96 lakh compared with Rs 644.22 lakh in the corresponding prior quarter. Basic and diluted earnings per share (Rs 10 each, not annualised) were both Rs 10.21 for the quarter, against Rs 9.08 in the same quarter of the previous year, as shown in the statement of financial results.
Track India Gelatine & Chemicals Ltd-$
Cruxal reads every India Gelatine & Chemicals Ltd-$ filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.